Annual General Meeting held
on May 10,
2024 - Poll
Results
Hong Kong, Shanghai, & Florham Park, NJ: Friday, May
10, 2024: HUTCHMED (China) Limited ("HUTCHMED" or
the "Company") (Nasdaq/AIM: HCM; HKEX:13) today announces that all
ordinary resolutions and the special resolution put to its Annual
General Meeting ("AGM") held on May 10, 2024
were duly passed. The poll results of the
resolutions were as follows:
|
Ordinary Resolutions
|
Number of Votes
(%)*
|
Passed by
Shareholders
|
|
For
|
Against
|
Withheld#
|
|
1.
|
To consider and adopt the audited
financial statements, and the reports of the directors and
independent auditors for the year ended December 31,
2023.
|
554,454,067
(93.5575%)
|
38,180,450
(6.4425%)
|
218,278
|
Yes
|
|
2(A).
|
To re-elect Mr TO Chi Keung, Simon
as a director.
|
562,917,369
(94.9555%)
|
29,905,093
(5.0445%)
|
30,333
|
Yes
|
|
2(B).
|
To re-elect Dr Weiguo SU as a
director.
|
592,306,222
(99.9129%)
|
516,240
(0.0871%)
|
30,333
|
Yes
|
|
2(C).
|
To re-elect Mr CHENG Chig Fung,
Johnny as a director.
|
592,007,486
(99.8625%)
|
814,976
(0.1375%)
|
30,333
|
Yes
|
|
2(D).
|
To re-elect Dr Dan ELDAR as a
director.
|
591,101,915
(99.7098%)
|
1,720,547
(0.2902%)
|
30,333
|
Yes
|
|
2(E).
|
To re-elect Ms Edith SHIH as a
director.
|
588,968,013
(99.3498%)
|
3,854,454
(0.6502%)
|
30,328
|
Yes
|
|
2(F).
|
To re-elect Ms Ling YANG as a
director.
|
584,012,135
(98.5138%)
|
8,810,327
(1.4862%)
|
30,333
|
Yes
|
|
2(G).
|
To re-elect Mr Paul Rutherford
CARTER as a director.
|
534,646,546
(90.1866%)
|
58,175,756
(9.8134%)
|
30,493
|
Yes
|
|
2(H).
|
To re-elect Mr Graeme Allan JACK as
a director.
|
570,023,306
(96.1541%)
|
22,799,126
(3.8459%)
|
30,363
|
Yes
|
|
2(I).
|
To re-elect Professor MOK Shu Kam,
Tony as a director.
|
582,250,508
(98.2167%)
|
10,571,949
(1.7833%)
|
30,338
|
Yes
|
|
3.
|
To re-appoint PricewaterhouseCoopers
and PricewaterhouseCoopers Zhong Tian LLP as the Auditors of the
Company for Hong Kong financial reporting and U.S. financial
reporting purposes, respectively, and to authorize the Directors to
fix the Auditors' remuneration.
|
592,416,337
(99.9339%)
|
391,725
(0.0661%)
|
44,733
|
Yes
|
|
Special Resolution
|
|
4.
|
To grant a general mandate to the
Directors to issue additional shares of the Company.^
|
589,480,694
(99.4384%)
|
3,329,371
(0.5616%)
|
42,730
|
Yes
|
|
Ordinary Resolution
|
|
5.
|
To grant a general mandate to the
Directors to repurchase shares of the Company.^
|
592,794,880
(99.9974%)
|
15,185
(0.0026%)
|
42,730
|
Yes
|
* Percentages rounded to 4 decimal
places.
# A vote withheld is not a
vote in law and is not counted in the calculation of the proportion
of the votes for and against a resolution.
^
The full text of Resolutions 4 and 5 are set out in the Notice of
AGM.
Notes:
(1) All directors of the Company, namely
Mr TO Chi Keung, Simon, Dr Weiguo SU, Mr CHENG Chig Fung, Johnny,
Dr Dan ELDAR, Ms Edith SHIH, Ms Ling
YANG, Mr Paul Rutherford CARTER, Mr Graeme
Allan JACK and Professor MOK Shu Kam, Tony, attended the AGM,
either in person or by means of electronic facilities.
(2) Number of shares
entitling the holders to attend and vote on all the resolutions at
the AGM: 871,264,820 shares.
(3) Number of
shares entitling the holders to attend and abstain from voting in
favour as set out in Rule 13.40 of the Rules Governing the Listing
of Securities on The Stock Exchange of Hong Kong Limited (the
"Listing Rules") at the AGM: Nil.
(4) Number of shares for
holders required under the Listing Rules to abstain from voting at
the AGM: Nil.
(5) The scrutineer for the
poll at the AGM was Computershare Investor Services (Jersey)
Limited, the Principal Share Registrar of the Company.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13)
is an innovative, commercial-stage, biopharmaceutical company. Іt
is committed to the discovery and global development and
commercialization of targeted therapies and immunotherapies for the
treatment of cancer and immunological diseases. Іt has
approximately 5,000 personnel across all its companies, at the
center of which is a team of about 1,800 in oncology/immunology.
Since inception, HUTCHMED has focused on bringing cancer drug
candidates from in-house discovery to patients around the world,
with its first three medicines marketed in China, the first of
which is also marketed in the U.S. For more
information, please visit: www.hutch‑med.com
or follow us on LinkedIn.
CONTACTS
Investor Enquiries
|
|
Media Enquiries
|
|
|
Ben Atwell / Alex Shaw,
FTI Consulting
|
+44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
|
|
Zhou Yi, Brunswick
|
+852 9783 6894 (Mobile) /
HUTCHMED@brunswickgroup.com
|
Nominated Advisor
|
|
|
Atholl Tweedie /
Freddy Crossley / Daphne Zhang,
Panmure Gordon
|
+44 (20) 7886 2500
|